Women with ovarian, breast, skin, and uterine cancers were found to have significantly higher levels of per- and polyfluoroalkyl substances (PFAS), phenols, and parabens in their bodies.
Women with ovarian, breast, skin, and uterine cancers were found to have significantly higher levels of "forever" chemicals in their bodies, according to research published in the Journal of Exposure Science and Environmental Epidemiology.1
Forever chemicals are per- and polyfluoroalkyl substances (PFAS), which are manmade chemicals commonly found in everyday items, especially in products that are heat, oil, stain, grease, and water resistant, according to the CDC.2 The study also looked at phenols like bisphenol A (BPA), as well as parabens.
Using data from the National Health and Nutrition Examination Survey (NHANES), researchers evaluated cross-sectional associations between these forever chemicals and cancer diagnoses. This was done by measuring the levels of 7 PFAS and 12 phenols and parabens, along with self-reported diagnoses of melanoma, thyroid, breast, ovarian, uterine, and prostate cancers among nearly 50,000 adults aged 20 years and older.
The 7 PFAS included were perfluorohexane sulfonic acid (PFHS), 2-(N-methyl-PFOSA) acetic acid (MPAH), perfluorodecanoic acid (PFDE), perfluorononanoic acid (PFNA), perfluoroundecanoic acid (PFUA), perfluorooctanoic acid (PFOA), and perfluorooctane sulfonic acid (PFOS). The 12 phenols and parabens were BPA, benzophenone-3 (BP3), triclosan (TCS), methyl paraben (MPB), ethyl paraben (EPB), propyl paraben (PPB), butyl paraben (BPB), bisphenol-F (BPF), bisphenol-S (BPS), triclocarban (TCC), 2,4-dichlorophenol (DCP24), and 2,5-dichlorophenol (DCP25).
In women, a history of melanoma was linked to elevated levels of the following chemicals:
“Importantly, melanoma is the fifth most common cancer in the U.S. and recent estimates indicate increasing incidence in higher-income countries,” the study authors said. “While the proportion of melanoma diagnoses is higher among White individuals, survival rates have been shown to be significantly lower among individuals who are Black, Hispanic, Asian American, Native American, and Pacific Islander.”
Additionally, previous ovarian cancer was associated with higher levels of the following:
In cases of previous uterine cancer, PFNA was positively associated (OR, 1.55; 95% CI, 1.03-2.34), while ethyl paraben showed an inverse association (OR, 0.31; 95% CI, 0.12-0.85). Additionally, various PFAS were connected to previous ovarian and uterine cancers among White women, while non-White women demonstrated associations between MPAH or BPF and previous breast cancer.
The study authors made sure to note that these findings do not immediately point to a causal relationship between PFAS and cancer, and that more research is needed to explore that idea.
“While we would have liked to account for the time between cancer diagnoses and biomarker measurement, this information was not available in NHANES,” the authors said. “Further, because our exposures were measured after the cancer diagnoses occurred, reverse causation is a possibility if behavioral changes occurred. Subsequent treatment for cancer may also influence concentrations of endocrine-disrupting chemicals through altered metabolism, which may also be an important source of exposure misclassification among those with previous cancer diagnoses.”
They also noted that the study’s findings show a “sexually dimorphic nature” of risk for melanoma, and a “potential estrogen-dependent mechanism” for both melanoma and ovarian cancer.
“We also showed differential associations between environmental exposures and previous cancer diagnoses by racial groups, underscoring racial disparities that exist both in innate risk of cancer outcomes and in exposures to environmental toxicants,” they said. “Future work in prospective cancer studies should aim to explore the roles of estrogenic chemicals and estrogen disruption in the pathology of melanoma and ovarian cancer and consider racial disparities when evaluating cancer mechanisms and risk."
They also concluded that the findings from this study can help inform and prioritize the types of toxicants that should be targeted by policies for surveillance of chemical exposure, as well as assess risk in communities where there is environmental contamination.
References
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More